Self-Emulsifying Antifungal Composition for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antifungal drugs like BAL 4815 and ravuconazole have low bioavailability due to poor solubility in aqueous media, limiting their effectiveness in oral administration for systemic mycoses, and existing self-emulsifying drug delivery systems are not universally applicable across different chemical structures.
Innovation Solution
Formulating these antifungal drugs as self-emulsifying or self-microemulsifying drug delivery systems comprising a mixture of glycerol mono- and di-esters, polyethylene glycol mono- and di-esters with fatty acids, and surfactants like Gelucire and Labrasol, which form fine emulsions or microemulsions in gastrointestinal fluids, enhancing solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antifungal drugs are formulated as conventional oral medications, then they can be administered orally, but their bioavailability is low due to poor solubility in aqueous media
Solution Approach 1:
The patent introduces self-emulsifying excipients (surfactants and co-surfactants) as intermediary substances that mediate between the lipophilic antifungal drug and the aqueous gastrointestinal fluids. These excipients form microemulsions that solubilize the drug, enabling its absorption without requiring the drug itself to be water-soluble.
Solution Approach 2:
The patent changes the physical state and surface properties of the formulation by incorporating surfactants that reduce surface tension and enable spontaneous emulsification. This parameter change transforms the drug delivery system from a simple solid or liquid formulation into a self-emulsifying system that dynamically adapts to aqueous environments.
2Reliability
If self-emulsifying drug delivery systems are designed for one chemical structure, then they improve bioavailability for that specific drug, but they are not universally applicable to drugs with different chemical structures
Solution Approach 1:
The patent develops a universal self-emulsifying formulation platform using a specific combination of excipients (Labrafil M 1944 CS, Labrasol, Transcutol P, and Cremophor EL) that can effectively deliver multiple antifungal drugs with different chemical structures (ravuconazole, BAL 4815, itraconazole, posaconazole). This multi-functional system overcomes the limitation of structure-specific formulations.
3Object-affected harmful factors
If prodrugs are designed to improve water solubility, then solubility increases, but the complexity of the molecule increases and may affect the drug's antifungal activity
Solution Approach 1:
Instead of modifying the drug molecule itself (which would increase molecular complexity), the patent segments the formulation into distinct components: the unchanged antifungal drug and separate self-emulsifying excipients. This approach improves water solubility through formulation rather than molecular modification, preserving the drug's original structure and activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The self-emulsifying systems improve the absorption rate and extent of antifungal compounds, providing more reproducible blood-time profiles and increased bioavailability, making them suitable for oral treatment of systemic mycoses like disseminated aspergillosis.
Implementation Method 1
these systems tend to instantly form micelles when coming into contact with aqueous media, in particular gastrointestinal fluids, thus leading to pseudo-solubilization and enhanced absorption of the drug
Implementation Method 2
compositions of matter comprising a lipid phase for dissolving the lipophilic drug and one or more suitable surfactant(s)/co-surfactants
Implementation Method 3
a lipid phase for dissolving the lipophilic drug
Data Source
AI summary
A pharmaceutical composition for oral administration which is self-emulsifying on contact with an aqueous phase, in particular gastrointestinal fluids, and which comprises: (a)an antifungally active compound of formula (I) wherein R1, R2 and R3 are independently of one another hydrogen, F or Cl; or a pharmaceutically acceptable acid addition salt thereof, and (b)a carrier comprising a solubilizer component for the antifungally effective component (a).